Vitiligo Clinical Trials 2025: EMA, PDMA, FDA Approvals, NDA, Medication, IND, Treatment market, ROA, MOA and Companies by DelveInsight | AbbVie, Pfizer, Incyte Corporation, Ahammune Biosciences, Amgen

(Nevada, United States) As per DelveInsight's assessment, globally, Vitiligo pipeline constitutes 22+ key companies continuously working towards developing 22+ Vitiligo treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Vitiligo Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Vitiligo Market.
The Vitiligo Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/report-store/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Vitiligo Pipeline Report:
• Vitiligo Companies across the globe are diligently working toward developing novel Vitiligo treatment therapies with a considerable amount of success over the years.
• Vitiligo companies working in the treatment market are Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Science, Amgen, Pfizer, Incyte Corporation, Clinuvel Pharmaceuticals, and others, are developing therapies for the Vitiligo treatment
• Emerging Vitiligo therapies in the different phases of clinical trials are- Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, Afamelanotide, Crisaborole 2% Topical Ointment, and others are expected to have a significant impact on the Vitiligo market in the coming years.
• In January 2025, VYNE Therapeutics completed patient enrollment in its Phase 2b trial assessing VYN201 gel (repibresib) for the treatment of nonsegmental vitiligo. The company anticipates reporting top-line data from the 24-week vehicle-controlled treatment phase in mid-2025. This trial marks a significant milestone in the development of VYN201, which VYNE believes could become a unique treatment option for vitiligo patients. Additionally, the United States Adopted Names (USAN) Council has officially recognized "repibresib" as the non-proprietary name for the new chemical entity in VYN201.
• In May 2024, Edesa Biotech, Inc. (NASDAQ: EDSA) is preparing to launch a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo in patients. Vitiligo is a condition where certain areas of the skin lose color, and non-segmental vitiligo is marked by patches on both sides of the body. This condition occurs when pigment-producing cells (melanocytes) either die or stop producing melanin, often due to autoimmune diseases, genetics, or a triggering event such as stress, sunburn, or skin trauma.
• In July 2024, the US FDA approved a groundbreaking treatment for vitiligo, a chronic immune-mediated skin disorder characterized by depigmented white patches on the skin.
• In October 2023, Incyte has released favorable long-term extension (LTE) findings from the TruE-V trial, evaluating the safety and effectiveness of Opzelura (ruxolitinib) as a therapy for nonsegmental vitiligo. This study involved patients who had previously shown no improvement from the treatment after 24 weeks of use.
• AnaptysBio is entering a Phase 1 study with healthy volunteers for their ANB030 (Anti-PD-1 Agonist) program; top-line data are expected in mid-2021. Phase 2 clinical studies for vitiligo and alopecia areata are planned for Q4 2021, assuming all goes according to plan.

Vitiligo Overview
A complicated pigment condition affecting the skin, hair, and occasionally the mucous membranes is called vitiligo. Though it can occur on any part of the skin, vitiligo usually affects the hands, neck, and face. Clinically, vitiligo manifests as milk-white, irregularly oval skin patches that start out small and grow over time.

Get a Free Sample PDF Report to know more about Vitiligo Pipeline Therapeutic Assessment - https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Vitiligo Drugs Under Different Phases of Clinical Development Include:
• Phimelanotide: Clinuvel Pharmaceuticals
• BNZ-1: Bioniz Therapeutics
• TAGX-0003: TAGCyx Biotechnologies
• TT-01: Temprian Therapeutics
• ATI-1777: Aclaris Therapeutics
• AC-1101: TWi Biotechnology
• Cerdulatinib: Dermavant Science
• AMG 714: Amgen
• Ritlecitinib: Pfizer
• Ruxolitinib: Incyte Corporation
• Afamelanotide: Clinuvel Pharmaceuticals Limited
• Crisaborole 2% Topical Ointment: Pfizer

Vitiligo Route of Administration
Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.

Request for sample report @ https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Vitiligo Molecule Type
Vitiligo Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Vitiligo Pipeline Therapeutics Assessment
• Vitiligo Assessment by Product Type
• Vitiligo By Stage and Product Type
• Vitiligo Assessment by Route of Administration
• Vitiligo By Stage and Route of Administration
• Vitiligo Assessment by Molecule Type
• Vitiligo by Stage and Molecule Type

DelveInsight's Vitiligo Report covers around 22+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Vitiligo product details are provided in the report. Download the Vitiligo pipeline report to learn more about the emerging Vitiligo therapies - https://www.delveinsight.com/report-store/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Vitiligo Therapeutics Market include:
Key companies developing therapies for Vitiligo are - Dermavant Sciences, Incyte Corporation, TWi Biotechnology, Aclaris Therapeutics, Dermira, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, Bioniz Therapeutics, among others.

Vitiligo Pipeline Analysis:
The Vitiligo pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Vitiligo with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vitiligo Treatment.
• Vitiligo key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Vitiligo Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vitiligo market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Vitiligo drugs and therapies - https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Vitiligo Pipeline Market Drivers
Increasing awareness, demand of novel therapies, large patient pool and better healthcare infrastructure are some of the important factors that are fueling the Vitiligo Market.

Vitiligo Pipeline Market Barriers
However, patient compliance, chronic nature of disease and long term therapy, lack of adequate financial assistance & stringent regulatory procedure and other factors are creating obstacles in the Vitiligo Market growth.

Scope of Vitiligo Pipeline Drug Insight
• Coverage: Global
• Key Vitiligo Companies: Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Science, Amgen, Pfizer, Incyte Corporation, Clinuvel Pharmaceuticals, and others
• Key Vitiligo Therapies: Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, Afamelanotide, Crisaborole 2% Topical Ointment, and others
• Vitiligo Therapeutic Assessment: Vitiligo current marketed and Vitiligo emerging therapies
• Vitiligo Market Dynamics: Vitiligo market drivers and Vitiligo market barriers

Request for Sample PDF Report for Vitiligo Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Vitiligo Report Introduction
2. Vitiligo Executive Summary
3. Vitiligo Overview
4. Vitiligo- Analytical Perspective In-depth Commercial Assessment
5. Vitiligo Pipeline Therapeutics
6. Vitiligo Late Stage Products (Phase II/III)
7. Vitiligo Mid Stage Products (Phase II)
8. Vitiligo Early Stage Products (Phase I)
9. Vitiligo Preclinical Stage Products
10. Vitiligo Therapeutics Assessment
11. Vitiligo Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Vitiligo Key Companies
14. Vitiligo Key Products
15. Vitiligo Unmet Needs
16 . Vitiligo Market Drivers and Barriers
17. Vitiligo Future Perspectives and Conclusion
18. Vitiligo Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Allergic Rhinitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Alstrom Syndrome Market: https://www.delveinsight.com/report-store/alstrom-syndrome-market
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Angioedema Market: https://www.delveinsight.com/report-store/hereditary-angioedema-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Artificial Iris Market: https://www.delveinsight.com/report-store/artificial-iris-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-market
• Astigmatism Market: https://www.delveinsight.com/report-store/astigmatism-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Hemolytic Uremic Syndrome Ahus Market: https://www.delveinsight.com/report-store/atypical-hemolytic-uremic-syndrome-ahus-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Bacterial Skin Diseases Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Biliary Tumor Market: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Bladder Cancer Market: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/competitive-intelligence-services
Case study: https://www.delveinsight.com/case-study/hematological-malignancy-competitive-intelligence

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.